Insider Cluster (2 insiders) ·Filed Aug 7, 2026

JNJ

JOHNSON & JOHNSON
NEUTRAL
Impact 3/10
Horizondays Processed1mo ago
Insider cluster: 2 insiders, $4.1M total
Actionable Insight • Neutral

Insider sales at this magnitude relative to market cap are routine. Duato's 10b5-1 plan likely governs these sales post-vesting. No actionable signal — monitor next 8-K or earnings for any material change in fundamentals.

DirectionNeutral
Confidencehigh
Horizondays
Latest settled — T+20d ⚠ clustered
JNJ ▲ +2.79% at T+20d
NEUTRAL call ✓ call won +2.79% · α vs SPY +3.71% · entry $261.81 → $269.12
Next anchor: T+60d in 4w
Latest observation: T+36 -4.04% FF3 residual α
Entry anchored
Aug 7, 05:50 PM ET
via 1-min bar
T+1d
-0.77%
call -0.77% · α -0.45%
$259.80
settled 8w ago
T+5d
+0.21%
call +0.21% · α +0.26%
$262.37
settled 7w ago
T+20d
+2.79%
call +2.79% · α +3.71%
$269.12
settled 28d ago
T+60d
—
call — · α —
—
in 4w

Price Chart

Loading chart...

Executive Summary

JNJ CEO Joaquin Duato and EVP/Chief Legal Officer Elizabeth Forminard executed ~$16.6M in open-market sales over two days. The CEO's $12.5M sale and CLO's combined $4.1M sale are modest relative to JNJ's $619B market cap (~0.0027%), making this a routine portfolio diversification event with negligible signal in a mega-cap pharmaceutical stock.

Key Financial Metrics

Direction
selling
Total Value
$16.6M
Insiders
2

Key Facts

  • CEO Joaquin Duato sold 48,480 shares for ~$12.5M on 2026-08-05
  • EVP/Chief Legal Officer Elizabeth Forminard sold 15,918 shares for ~$4.1M on 2026-08-06
  • Forminard's sales followed the exercise of 9,344 derivative shares at $131.94 (cash exercise) and 9,344 shares at $0 (non-cash)
  • Total open-market sales of ~$16.6M represent ~0.0027% of JNJ's $619B market cap

Financial Impact

$16.6M in insider sales, immaterial relative to $619B market cap

Risk Factors

  • Large insider sales from senior executives could be misread by retail traders as a negative signal
  • Historical model performance on JNJ filing reports shows a 38% win rate at T+20 — prior bearish calls have underperformed

Market Snapshot

Price
$259.28
Volume
100
Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
71% bullish (31 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-JNJ-1786140079824
16 reports for JNJ
Performance horizon
60% Hit rate 3 of 5 directional calls best @ T+60▲ +13.24%May 13, 2026
Filters
Rows
Reports for JNJ — sortable, filterable
TypeNow
Sep 9, 2026
23d ago
Court Ruling
NEUTRAL ★ 1/10
$267.08 $267.28▲ +0.07%▲ +0.73%$258.66 (−3.15%)
Aug 18, 2026
6w ago
Insider Cluster
NEUTRAL ★ 2/10
$273.41 $270.00▼ −1.25%▼ −0.86%$258.66 (−5.39%)
Aug 14, 2026
7w ago
Insider Cluster
NEUTRAL ★ 2/10
$260.35 $270.24▲ +3.80%▲ +5.17%$258.66 (−0.65%)
Aug 7, 2026
7w ago
Insider Cluster
NEUTRAL ★ 3/10
$261.81 $262.37▲ +0.21%▲ +0.26%$258.66 (−1.20%)
Aug 7, 2026
8w ago
Court Ruling
BEARISH ★ 4/10
$259.24 $260.35▼ −0.43%▼ −0.03%$258.66 (+0.22%)
Aug 4, 2026
8w ago
8-K
NEUTRAL ★ 2/10
$254.93 $259.80▲ +1.91%▲ +2.01%$258.66 (+1.46%)
Jul 22, 2026
10w ago
Court Ruling
BEARISH ★ 7/10
$255.63 $265.53▼ −3.87%▼ −6.27%$258.66 (−1.19%)
Jul 15, 2026
11w ago
8-K
BULLISH ★ 6/10
$247.02 $255.63▲ +3.49%▲ +4.47%$258.66 (+4.71%)
May 20, 2026
19w ago
Court Ruling
NEUTRAL ★ 1/10
$229.12 $231.29▲ +0.95%▼ −0.29%$258.66 (+12.89%)
May 13, 2026
20w ago
ANALYST-UPGRADE
BULLISH ★ 3/10
$230.79 $231.58▲ +0.34%▲ +1.06%$258.66 (+12.08%)
Showing 10 of 16

US Market Status

Market Closed — Opens in 4m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Aug 7, 2026